Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naluzotan

Next Previous
Drug Profile

Naluzotan

Alternative Names: PRX-00023

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer EPIX Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Proximagen
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfonamides
  • Mechanism of Action Serotonin 1A receptor agonists; Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Drug-induced dyskinesia; Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Oct 2017 National Institute of Neurological Disorders and Stroke terminates phase II trial in Epilepsy in USA (NCT01281956)
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top